Phase II study of dual phosphoinositol-3-kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma (TCC)
Seront, E., Rottey, S., Filleul, B., Glorieux, P., Goeminne, JC., Verschaeve, V., Vandenbulcke, J-M., Sautois, B., Boegner, P., Gillain, A., van Maanen, A., Machiels, J-P.Language:
english
Journal:
BJU International
DOI:
10.1111/bju.13415
Date:
January, 2016
File:
PDF, 258 KB
english, 2016
File converter
More search results
More benefits 
